PURPOSE: Here, we studied whether amplicon next-generation deep sequencing (NGS) could improve the detection of emerging BCR-ABL1 kinase domain mutations in chronic phase chronic myeloid leukemia (CML) patients under tyrosine kinase inhibitor (TKI) treatment and discussed the clinical relevance of such sensitive mutational detection. METHODS: For NGS data evaluation including extraction of biologically relevant low-level variants from background error noise, we established and applied a robust and versatile bioinformatics approach. RESULTS: Results from a retrospective longitudinal analysis of 135 samples of 15 CML patients showed that NGS could have revealed emerging resistant mutants 2-11 months earlier than conventional sequencing. Interestingly, in cases who later failed first-line imatinib treatment, NGS revealed that TKI-resistant mutations were already detectable at the time of major or deeper molecular response. Identification of emerging mutations by NGS was mirrored by BCR-ABL1 transcript level expressed either fluctuations around 0.1 %(IS) or by slight transcript level increase. NGS also allowed tracing mutations that emerged during second-line TKI therapy back to the time of switchover. Compound mutants could be detected in three cases, but were not found to outcompete single mutants. CONCLUSIONS: This work points out, that next-generation deep sequencing, coupled with a robust bioinformatics approach for mutation calling, may be just in place to ensure reliable detection of emerging BCR-ABL1 mutations, allowing early therapy switch and selection of the most appropriate therapy. Further, prospective assessment of how to best integrate NGS in the molecular monitoring and clinical decision algorithms is warranted.

Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872–874 PubMed PMC

Bracho MA, Moya A, Barrio E (1998) Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity. J Gen Virol 79:2921–2928 PubMed

Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I et al (2008) Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. PNAS 105:13081–13086 PubMed PMC

Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880 PubMed

Grossmann V, Roller A, Klein HU, Weissmann S, Kern W, Haferlach C et al (2013) Robustness of amplicon deep sequencing underlines its utility in clinical applications. J Mol Diagn 15:473–484 PubMed

Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M et al (2008) Finding of kinase domain mutation in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26:4806–4813 PubMed PMC

Kohlmann A, Martinelli G, Alikian M, Artusi V, Auber B, Belickova M, et al (2013) The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: deep-sequencing analyses of hematological malignancies performed in 8,867 cases by an international network involving 27 laboratories [abstract]. 2013 annual meeting abstracts, Blood 122:743

Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376–383 PubMed PMC

Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957–1963 PubMed

Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP et al (2011) Sensitive detection of BCR-ABL11 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol 29:4250–4259 PubMed

Polakova KM, Polivkova V, Rulcova J, Klamova H, Jurcek T, Dvorakova D et al (2010) Constant BCR-ABL1 transcript level > or = 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Exp Hematol 38:20–26 PubMed

Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA (2012) Detection of ultra-rare mutation by next-generation sequencing. PNAS 109:14508–14513 PubMed PMC

Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al (2011) BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118:1208–1215 PubMed

Soverini S, De Benedittis C, Polakova KM, Brouckova A, Horner D, Iacono M et al (2013) Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL1 kinase domain. Blood 122:1364–1648 PubMed

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE et al (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive Leukemia. Cancer Cell. doi:10.1016/j.ccr.2014.07.006 PubMed PMC

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients